Supraventricular Tachycardia Causing Left Ventricular Dysfunction
Section snippets
Methods
All consecutive patients admitted for new-onset LV systolic dysfunction and concomitant evidence of sustained SVT with heart rate >100 bpm from January 2005 to December 2016 in the Cardiovascular Department of the University Hospital of Trieste were analyzed. Patients included in the study presented with LVEF <50% at baseline evaluation in the absence of any other known possible causes of systolic dysfunction. Therefore, patients with significant coronary artery disease, history of uncontrolled
Results
The study population included 83 patients. The complete baseline characteristics are summarized in Table 1 and Figure 1. Eighty-seven percent (72) patients underwent to effective rhythm control (27 patients with catheter ablation, 40 with DCCV and 5 with anti-arrhythmic drugs). The remaining 11 (13%) were treated with a rate control strategy for refusal by patients, persistent left atrium appendage/endo-ventricular thrombosis, ineffective rhythm control.
Enrolled patients were revaluated for a
Discussion
The main results of our study are: (1) 67% of patients presenting with new-onset LV dysfunction associated to high-rate sustained SVT as the only known possible cause, showed LVEF recovery after arrhythmia management at a median follow-up of > 4 years; (2) patients with recovered LVEF showed a higher overall survival rate with respect to patients with non-recovered LVEF; (3) 42% of patients with recovered LVEF at last evaluation had experienced arrhythmic recurrences during the follow-up and
Author’ Contribution
All persons who meet authorship criteria are listed as authors, and all authors certify that they have participated sufficiently in the work to take public responsibility for the content, including participation in the concept, design, analysis, writing, or revision of the manuscript. Furthermore, each author certifies that this material or similar material has not been and will not be submitted to or published in any other publication before its appearance in the Hong Kong Journal of
Disclosures
Denise Zaffalon's reports were provided by Azienda Sanitaria Universitaria Giuliano-Isontina. Denise Zaffalon reports a relationship with Azienda Sanitaria Integrata Giuliano-Isontina that includes: nonfinancial support. Denise Zaffalon has patent pending to Not available. None.
Acknowledgment
This paper is dedicated to the memory of Professor Fulvio Camerini, foremost expert in cardiomyopathies, outstanding clinician and scientist. We would like to thank Fondazione CRTrieste, and FINCANTIERI for their support. We are also grateful to all the healthcare professionals for the continuous support to research and clinical management of patients and families with CMPs followed in the HF Outpatient Clinic and CMPs Center of Trieste.
References (20)
- et al.
Arrhythmia-induced cardiomyopathies: mechanisms, recognition, and management
J Am Coll Cardiol
(2015) - et al.
Arrhythmia-induced cardiomyopathy: JACC state-of-the-art review
J Am Coll Cardiol
(2019) - et al.
Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
J Am Soc Echocardiogr
(2016) - et al.
ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter- defibrillators and cardiac resynchronization therapy
J Am Coll Cardiol
(2013) - et al.
Genetic etiology for alcohol-induced cardiac toxicity
J Am Coll Cardiol
(2018) - et al.
Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS)
Europace
(2019) - et al.
Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia
Circulation
(2004) - et al.
Evolving concepts in dilated cardiomyopathy
Eur J Heart Fail
(2018) - et al.
Contemporary survival trends and aetiological characterization in non-ischaemic dilated cardiomyopathy
Eur J Heart Fail
(2020) - et al.
Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American society of echocardiography and the European association of cardiovascular imaging
Eur Heart J Cardiovasc Imaging
(2015)
Cited by (3)
Pragmatic electrocardiogram tracings in non-ischaemic dilated cardiomyopathy: diagnostic and prognostic role
2023, European Heart Journal, SupplementClinical characterization and natural history of chemotherapy-induced dilated cardiomyopathy
2022, ESC Heart FailureDeep Learning-Based Electrocardiograph in Evaluating Radiofrequency Ablation for Rapid Arrhythmia
2022, Computational and Mathematical Methods in Medicine
Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-profit sectors.